
    
      This is an exploratory, randomized, partially blinded, multicenter clinical study designed to
      compare safety and biomarkers of varicella zoster virus immunogenicity when administering
      ZOSTAVAXâ„¢ (V211) at various doses both intradermally and subcutaneously in healthy male and
      female participants 50 years of age and older.
    
  